September 18, 2017 Licensing, IP, and Legal

Xylem to participate in the Cowen and Company 2nd Annual Industrial Innovation & Technology Summit

RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 18, 2017– Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its Senior Vice President and Chief Marketing Officer, Joseph Vesey, will participate in a panel discussion entitled, Water Panel – Maximizing Utility Across Municipal and Industrial Markets at... Read more

September 13, 2017 Licensing, IP, and Legal Life Science Tools PR/Corporate Product Launch

Cellular Dynamics International Presents Annual iForum Meetings Focused on New Applications and Uses for Differentiated Human iPS Cells

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Astrocytes iCell DopaNeurons iCell GABANeurons iCell GlutaNeurons iCell Motor Neurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more